A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.11, issue.7, pp.495-505, 2005. ,
DOI : 10.1016/j.bbmt.2005.03.006
Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings, Bone Marrow Transplantation, vol.15, issue.11, pp.1089-93, 2005. ,
DOI : 10.1038/sj.bmt.1704956
Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients, Therapeutic Drug Monitoring, vol.29, issue.3, pp.353-60, 2007. ,
DOI : 10.1097/FTD.0b013e31805d8816
Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings, Bone Marrow Transplantation, vol.27, issue.12 ,
DOI : 10.1038/sj.bmt.1703076
Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review, Transplantation, vol.85, issue.12 ,
DOI : 10.1097/TP.0b013e3181744199
A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.23, issue.6, pp.837-884, 2005. ,
DOI : 10.2165/00003088-200544080-00005
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods, Ther Drug Monit, issue.3, pp.354-61, 2005. ,
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation, Am J Transplant, issue.11, pp.2496-503, 2007. ,
Statistics of MMF dose adjustment on ISBA, a free website for dose adjustment of immunosuppressive drugs abstract, Ther Drug Monit, vol.29, issue.4, p.241, 2007. ,
Unrelated Donor Granulocyte Colony-Stimulating Factor???Mobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing, Biology of Blood and Marrow Transplantation, vol.12, issue.4, pp.454-65, 2006. ,
DOI : 10.1016/j.bbmt.2005.12.030
Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation, Bone Marrow Transplantation, vol.44, issue.2, pp.113-133, 2008. ,
DOI : 10.1016/S0041-1345(98)01926-5
Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation, Bone Marrow Transplantation, vol.33, issue.9 ,
DOI : 10.1038/sj.bmt.1704889
Simple and sensitive high-performance liquid chromatographic, J Chromatogr B Biomed Sci Appl, issue.1, pp.169-73, 2000. ,
Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.62, issue.4, pp.277-84, 2008. ,
DOI : 10.2165/00003088-200847040-00005
Application of a Gamma Model of Absorption to Oral Cyclosporin, Clinical Pharmacokinetics, vol.16, issue.5, pp.375-82, 2001. ,
DOI : 10.2165/00003088-200140050-00004
Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.21, issue.4, pp.1317-1345, 2005. ,
DOI : 10.2165/00003088-200544120-00010
Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets, Pharm Res, issue.12, pp.2748-59, 2006. ,
Alternative Approaches to Estimation of Population Pharmacokinetic Parameters: Comparison with the Nonlinear Mixed-Effect Model, Drug Metabolism Reviews, vol.82, issue.1-2 ,
DOI : 10.1007/BF01061210
Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments, Math Biosci, 1990. ,
Some suggestions for measuring predictive performance, Journal of Pharmacokinetics and Biopharmaceutics, vol.61, issue.4, pp.503-515, 1981. ,
DOI : 10.1007/BF01060893
Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients, British Journal of Clinical Pharmacology, vol.19, issue.2, pp.205-218, 2003. ,
DOI : 10.1046/j.1365-2125.2003.01871.x
Population Pharmacokinetics and Bayesian Estimator of Cyclosporine in Pediatric Renal Transplant Patients, Therapeutic Drug Monitoring, vol.29, issue.1, pp.96-102, 2007. ,
DOI : 10.1097/FTD.0b013e3180310f9d
Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation, Clinical Pharmacology & Therapeutics, vol.78, issue.5, pp.486-500, 2005. ,
DOI : 10.1016/j.clpt.2005.08.009
Prediction of Unbound Mycophenolic Acid Concentrations in Patients After Hematopoietic Cell Transplantation, Therapeutic Drug Monitoring, vol.29, issue.4, pp.385-90, 2007. ,
DOI : 10.1097/FTD.0b013e318074d979
A Limited Sampling Model for Estimation of Total and Unbound Mycophenolic Acid (MPA) Area Under the Curve (AUC) in Hematopoietic Cell Transplantation (HCT), Therapeutic Drug Monitoring, vol.28, issue.3, pp.394-401, 2006. ,
DOI : 10.1097/01.ftd.0000211821.73231.8a